MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
06 2020
Historique:
received: 20 01 2020
accepted: 13 05 2020
revised: 30 06 2020
pubmed: 20 6 2020
medline: 11 8 2020
entrez: 20 6 2020
Statut: epublish

Résumé

Human papillomaviruses (HPV) are a major cause of malignancy worldwide. They are the aetiological agents of almost all cervical cancers as well as a sub-set of other anogenital and head and neck cancers. Hijacking of host cellular pathways is essential for virus pathogenesis; however, a major challenge remains to identify key host targets and to define their contribution to HPV-driven malignancy. The Hippo pathway regulates epithelial homeostasis by down-regulating the function of the transcription factor YAP. Increased YAP expression has been observed in cervical cancer but the mechanisms driving this increase remain unclear. We found significant down-regulation of the master Hippo regulatory kinase STK4 (also termed MST1) in cervical disease samples and cervical cancer cell lines compared with healthy controls. Re-introduction of STK4 inhibited the proliferation of HPV positive cervical cells and this corresponded with decreased YAP nuclear localization and decreased YAP-dependent gene expression. The HPV E6 and E7 oncoproteins maintained low STK4 expression in cervical cancer cells by upregulating the oncomiR miR-18a, which directly targeted the STK4 mRNA 3'UTR. Interestingly, miR-18a knockdown increased STK4 expression and activated the Hippo pathway, significantly reducing cervical cancer cell proliferation. Our results identify STK4 as a key cervical cancer tumour suppressor, which is targeted via miR-18a in HPV positive tumours. Our study indicates that activation of the Hippo pathway may offer a therapeutically beneficial option for cervical cancer treatment.

Identifiants

pubmed: 32555725
doi: 10.1371/journal.ppat.1008624
pii: PPATHOGENS-D-20-00115
pmc: PMC7326282
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Intracellular Signaling Peptides and Proteins 0
MIRN18A microRNA, human 0
MicroRNAs 0
Oncogene Proteins, Viral 0
RNA, Neoplasm 0
Transcription Factors 0
Tumor Suppressor Proteins 0
YAP-Signaling Proteins 0
YAP1 protein, human 0
STK4 protein, human EC 2.7.1.11
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008624

Subventions

Organisme : Medical Research Council
ID : MR/K012665/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M011151/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S001697/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 1052221/Z/14/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/ K012665
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204825/Z/16/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/T00021X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102174/B/13/Z
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Cell Biol. 2003 Oct;5(10):914-20
pubmed: 14502294
Oncol Rep. 2015 Jun;33(6):2853-62
pubmed: 25963391
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
pubmed: 24591631
Cancer Res. 1996 Oct 15;56(20):4620-4
pubmed: 8840974
PLoS Pathog. 2019 Jun 21;15(6):e1007835
pubmed: 31226168
Sci Transl Med. 2016 Aug 17;8(352):352ra108
pubmed: 27535619
Oncogene. 2002 Sep 5;21(39):6041-8
pubmed: 12203116
Anticancer Res. 2012 Sep;32(9):3835-40
pubmed: 22993326
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731
Oncotarget. 2017 Jul 22;8(35):58061-58071
pubmed: 28938537
J Virol. 2003 May;77(10):6066-9
pubmed: 12719599
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817106
Nat Microbiol. 2016 Oct 31;2:16201
pubmed: 27798559
J Clin Invest. 2017 Apr 3;127(4):1338-1352
pubmed: 28240606
Oncogene. 2018 Sep;37(39):5257-5268
pubmed: 29855617
Expert Rev Mol Diagn. 2017 Jul;17(7):711-722
pubmed: 28597695
Dev Cell. 2010 Oct 19;19(4):491-505
pubmed: 20951342
Cell. 1993 Nov 5;75(3):495-505
pubmed: 8221889
Oncotarget. 2017 Oct 6;8(61):103581-103600
pubmed: 29262586
Cancer Gene Ther. 2010 Dec;17(12):827-36
pubmed: 20885450
Oncogenesis. 2014 Apr 21;3:e99
pubmed: 24752237
PLoS Pathog. 2018 Apr 9;14(4):e1006975
pubmed: 29630659
Nat Rev Drug Discov. 2014 Jan;13(1):63-79
pubmed: 24336504
J Med Virol. 1994 Nov;44(3):243-9
pubmed: 7852968
Oncogene. 1998 Jun 11;16(23):3029-37
pubmed: 9662336
Oncogene. 2001 Jun 7;20(26):3354-62
pubmed: 11423986
PLoS Med. 2005 Jul;2(7):e163
pubmed: 16033304
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
Carcinogenesis. 2011 Mar;32(3):389-98
pubmed: 21112960
Oncotarget. 2015 Dec 29;6(42):44466-79
pubmed: 26561204
Genes Dev. 2010 Jan 1;24(1):72-85
pubmed: 20048001
Mol Cancer Res. 2012 Jul;10(7):904-13
pubmed: 22618028
Cancer Cell. 2009 Nov 6;16(5):425-38
pubmed: 19878874
Oncogene. 2016 Aug 4;35(31):4048-57
pubmed: 26657153
Cell. 2003 Aug 22;114(4):445-56
pubmed: 12941273
Cancer Res. 2012 Oct 15;72(20):5418-27
pubmed: 22942253
Sci Rep. 2017 Oct 27;7(1):14265
pubmed: 29079854
PLoS Pathog. 2016 Aug 02;12(8):e1005766
pubmed: 27483446
J Biol Chem. 2010 Dec 10;285(50):39108-16
pubmed: 20921231
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Dev Dyn. 2009 Jul;238(7):1627-37
pubmed: 19517570
J Am Board Fam Med. 2015 Jul-Aug;28(4):498-503
pubmed: 26152442
Sci Rep. 2018 Jun 25;8(1):9636
pubmed: 29941883
Anticancer Res. 2008 May-Jun;28(3B):1763-6
pubmed: 18630456
EMBO Mol Med. 2015 Sep 28;7(11):1426-49
pubmed: 26417066
J Biol Regul Homeost Agents. 2019 Mar-Apr;33(2):321-330
pubmed: 30972994
Oncogene. 2013 Jan 3;32(1):106-16
pubmed: 22330141
Genes Chromosomes Cancer. 2008 Sep;47(9):755-65
pubmed: 18506748
Biochemistry. 2016 Oct 4;55(39):5507-5519
pubmed: 27618557
Heliyon. 2015 Dec 23;1(4):e00049
pubmed: 27441232
Cell. 2006 Jan 27;124(2):267-73
pubmed: 16439203
Cancers (Basel). 2018 Dec 05;10(12):
pubmed: 30563114
Gut. 2018 Sep;67(9):1692-1703
pubmed: 28866620
J Virol. 2020 Jun 1;94(12):
pubmed: 32238586

Auteurs

Ethan L Morgan (EL)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Molly R Patterson (MR)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Emma L Ryder (EL)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Siu Yi Lee (SY)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Christopher W Wasson (CW)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Katherine L Harper (KL)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Yigen Li (Y)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Stephen Griffin (S)

Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

G Eric Blair (GE)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Adrian Whitehouse (A)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Andrew Macdonald (A)

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, West Yorkshire, U.K, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH